A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2015
At a glance
- Drugs MK 8408 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 18 Jun 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.